This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Wednesday's Health Winners & Losers

Biotech stocks left something to be desired Wednesday, losing investor enthusiasm over breakups, regulatory setbacks and earnings.

Nastech (NSTK) fell after Procter & Gamble Pharmaceuticals, a unit of P&G (PG), terminated a development and commercialization agreement for Teriparatide, a nasal spray for treatment of osteoporosis. Nastech, which now regains rights to the drug, said it's immediately advancing it into a phase II clinical study on bone mineral density. It expects to recognize about $5.5 million in revenue in the fourth quarter due to termination of the P&G agreement.

Nastech shares slid $5.37, or 38%, to $8.62. It's a component of the Nasdaq biotechnology index, which was also down 22.7 points, or 2.6%, at 858.29.

Momenta (MNTA - Get Report) shed another 35 cents, or 6.2%, to $5.32 on Wednesday, as investors continued to react to the FDA's rejection of a generic form of blood-clotting drug Lovenox. Momenta, which partners with Novartis (NVS - Get Report) for the drug, on Tuesday said the FDA was concerned with the drug's immunogenicity, or whether the drug could produce an immune response. On Wednesday, the stock was downgraded by Deutsche Securities from buy to hold and by Rodman & Renshaw from market outperform to market perform.

One winner Wednesday was Onyx Pharmaceuticals (ONXX), which climbed $8.68, or 17.6%, to $58.03. The company said after the market close Tuesday that it earned $555,000, or a penny a share, compared to a loss of $20.1 million, or 49 cents a share, in the comparable year-ago period. Analysts surveyed by Thomson Financial had expected a loss of 21 cents a share.

Bayer, the company's partner for cancer drug Nexavar, reported that the drug generated revenue of $104.6 million in the quarter, up sharply from $45.4 million in the comparable year-ago period. On Wednesday analysts seemed enthusiastic about Nexavar sales -- Lehman Brothers upped its price target to $60 from $54; HSBC Securities upped its target to $61 from $44; and BMO Capital Markets raised its target to $46 from $41.
1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
CGPI $0.00 -28.57%
AEZS $4.17 -0.71%
MNTA $9.54 2.40%
NVS $76.36 -0.59%
GNVC $0.80 1.30%


Chart of I:DJI
DOW 17,777.48 -53.28 -0.30%
S&P 500 2,064.97 -10.84 -0.52%
NASDAQ 4,775.5350 -29.7560 -0.62%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs